Starpharma : CBCD Congratulates Starpharma (SPHRY) on the

New Post Public Reply Private Reply Replies (0) Message Board
tamerg

Starpharma : CBCD Congratulates Starpharma (SPHRY) on the Development of Its Virus Killing Condom
08/18/2014 | 12:01am US/EasternRecommend:
0
Rochester, NY (PRWEB) August 18, 2014

"Infected with the genital herpes virus (HSV-2)? The CBCD recommends taking Novirin or Gene-Eden-VIR." - Greg Bennett, CBCD

The Center for the Biology of Chronic Disease (CBCD) congratulates Starpharma, an Australian biomedical company, on the development of "a condom coated with a special gel that has been able to deactivate as much as 99.9 percent of viruses in laboratory testing." (1) The antiviral gel is called VivaGel and is designed to deactivate or destroy HIV, the herpes virus and the human papillomavirus (HPV), and will be marketed in Australia under the brand name LifeStyles Dual Protect. (1) So far, the condoms are only approved by the Australian health authorities. The CBCD looks forward to seeing a reduction in HPV, HSV, and HIV diagnoses in the Australian public, and to the introduction of these condoms to the American market. However, the CBCD reminds the public that approval of these condoms for American markets by the FDA may take time. Until then, the CBCD recommends two natural, safe and effective, HSV-2 remedies that are backed by clinical studies.

Click to learn more about genital herpes symptoms.

The Center for the Biology of Chronic Disease (CBCD) recommends that people infected with the genital herpes virus (HSV-2) take Novirin or Gene-Eden-VIR. The formula of these natural antiviral products was tested by Hanan Polansky and Edan Itzkovitz from the CBCD in two clinical studies that followed FDA guidelines. The studies showed that the Novirin and Gene-Eden-VIR formula is effective against the herpes simplex virus, and other viruses. The clinical studies were published in the peer reviewed, medical journal Pharmacology & Pharmacy, the first, in a special edition on Advances in Antiviral Drugs. Study authors wrote that, "individuals infected with the HSV … reported a safe decrease in their symptoms following treatment with Gene-Eden-VIR." (2) The study authors also wrote that, "we observed a statistically significant decrease in the severity, duration, and frequency of symptoms." (2)

Both products can be ordered online on the Novirin and Gene-Eden-VIR websites.

Novirin and Gene-Eden-VIR are natural antiviral dietary supplements. Their formula contains five natural ingredients: Selenium, Camellia Sinesis Extract, Quercetin, Cinnamomum Extract, and Licorice Extract. The first ingredient is a trace element, and the other four are plant extracts. Each ingredient and its dose was chosen through a scientific approach. Scientists at polyDNA, the company that invented and patented the formula, scanned thousands of scientific and medical papers published in various medical and scientific journals, and identified the safest and most effective natural ingredients against latent viruses. To date, Novirin and Gene-Eden-VIR are the only natural antiviral products on the market with published clinical studies that support their claims.

Even though the new condoms from Starpharma are coated with an antiviral gel, the CBCD reminds the public that genital herpes can be transmitted even when using condoms. As the CDC notes on its website, while condom use can reduce the risk of herpes transmission, "outbreaks can occur in areas that are not covered by a condom." (See the CDC, last updated February 13, 2013) (3)

What current treatments are available for herpes infections?

"Two types of antiviral treatments against HSV are available: topical and oral. The treatments include penciclovir, acyclovir, famciclovir, and valaciclovir. However, their effectiveness is limited. For instance, a meta-analysis of five placebo-controlled and two dose comparison studies evaluated the effect of aciclovir, famciclovir or valaciclovir on symptoms. The meta-analysis showed that oral antiviral therapy decreases the duration and the associated pain of an outbreak by merely one day." (2). There are also natural antiviral products that studies show to be safe and effective in reducing herpes symptoms. Two of these products are Novirin and Gene-Eden-VIR.

"There are currently no FDA approved antiviral coated condoms against the genital herpes virus. Research shows that most drugs against HSV-2 only reduce outbreaks by one day. Thus, we recommend that infected individuals take Novirin or Gene-Eden-VIR, which are designed to help the immune system target the latent HSV-2." - Greg Bennett, CBCD

Interested individuals can view the two published studies on the Novirin and Gene-Eden-VIR formula here: http://www.scirp.org/journal/PaperInformation...-x7BeOSz90 and http://www.scirp.org/journal/PaperInformation...erID=44234.

To learn more about Novirin, visit http://www.novirin.com and about Gene-Eden-VIR, visit http://www.gene-eden-vir.com.

References:

(1) NYDailynews.com - Condoms armored with virus-killing lubricant will soon be available. Published July 24, 2014.
nydailynews.com/life-style/health/condoms-virus-killing-lube-article-1.1878467

(2) Polansky, H. Itzkovitz, E. Gene-Eden-VIR Is Antiviral: Results of a Post Marketing Clinical Study. Published in September 2013. http://www.scirp.org/journal/PaperInformation...-x7BeOSz90

(3) CDC.com - Genital Herpes - CDC Fact Sheet. Last updated on February 13, 2013.
cdc.gov/std/herpes/stdfact-herpes-detailed.htm

Read the full story at http://www.prweb.com/releases/2014/08/prweb12095579.htm

Starpharma Holdings Ltd. (SPHRY) Stock Research Links

SPHRY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Megan Holdings Investors Face Deadline for Class Action

Updated Category News Views 1

Forgive my bluntness, but if you've been snoozing on your Megan Holdings Limited (NASDAQ:MGN) shares, it's time to wake up and smell the lawsuit papers. They're flying around faster than news at a market crash. If you snagged those shares between September 26, 2025, and March 25, 2026, or got in during the IPO on September 26, 2025, here's the deal: the deadline looms on...

Continue Reading
Ribbonwire Ranch Hits Sheetz Milestone with Campaign

Updated Category News Views 5

Where Beef Snacks Meet Road Tales Just a year ago, Ribbonwire Ranch, a small Texas-based beef snack producer, made its debut at Sheetz stores. Now, they're not just another brand on the shelf; they're weaving tales from the road with their latest venture, the "Dashboard Diaries" campaign. If you're wondering how a beef snack producer finds itself in an eight-week...

Continue Reading
Photronics Investors Must Act by Sept. 4, 2026 Deadline

Updated Category News Views 3

Action Time for Photronics Investors There's nothing like a looming deadline to get the adrenaline pumping, especially when you're staring down the barrel of a federal securities class action. Photronics, Inc. (NASDAQ: PLAB) has found itself tangled in legal webs, with the clock ticking down to September 4, 2026. That’s the deadline for investors to move on being the...

Continue Reading
Innovative Lighting Idea Brightens Indoor Lives

Updated Category News Views 3

Shedding Light on SUN ORB's Indoor Revolution Sometimes, the best ideas come from simple needs, like wanting a bit of sunshine in your life. That's the deal with this SUN ORB concept—an invention dreamed up by a chap from Oklahoma who's spent too much time away from the natural light outside. We're talking about a wellness-oriented lighting idea that has big ambitions...

Continue Reading
LG Electronics Unveils Smart Home Innovations at IFA

Updated Category News Views 1

Alright, let's dive into this world of shiny new gadgets that LG Electronics has trotted out at the IFA 2026. As European homes get cozier, folks aren't just after any appliance—they're seeking ones that blend smarts, efficiency, and style. So, LG's rolling out seven of their latest and supposedly greatest home appliances, hoping they'll hit the mark with the modern...

Continue Reading
Jim Morey Joins Pickleman's to Drive Expansion

Updated Category News Views 3

Jim Morey: Catalyst for Pickleman's Ambitious Dreams You ever heard of a sandwich joint ready to take on the big leagues? Because that's just what Pickleman's Gourmet Café is banking on with their latest move—tapping none other than Jim Morey for their executive advisory board. And let me tell ya, this ain't some run-of-the-mill hire. We're talking about a guy who's...

Continue Reading
Haier and UEFA's Deal: A Game-Changer for Fans?

Updated Category News Views 1

A Bold Play in the Global Arena There's something big brewing on the horizon, as Haier aligns with the UEFA Champions League. From 2027 to 2031, this move isn't just about slapping a logo on a jersey. Nah, it's more than that. Haier's stepping up its game, aiming to become a real player in weaving technology and sports into the daily lives of millions. "We aim to bring...

Continue Reading
Faruqi & Faruqi Urge Wix Investors to Act Now

Updated Category News Views 3

Ticking Clock for Wix Investors' Legal Moves The buzz in the stock market is louder than a bull on Wall Street, especially if you're tangled up with Wix.com Ltd. (NASDAQ: WIX). We've got Faruqi & Faruqi, LLP laying down serious advice: move fast or maybe lose your spot in line. The deadline to noodle over your position as a lead plaintiff in their federal securities class...

Continue Reading
Sunseeker Unveils 2027 LiDAR Models at IFA 2026

Updated Category News Views 0

Big Moves at IFA 2026 Sunseeker’s latest unveiling at IFA 2026 in Berlin signals a bold leap. They’re stepping beyond the usual automated mowers to unveil a comprehensive, high-tech garden ecosystem for 2027. It’s not just about lawn care anymore; it’s about integrating AI and robotics into our everyday green spaces. This isn’t just tinkering with your garden;...

Continue Reading
SimpliTrain's Momentum in LMS Market Heating Up

Updated Category News Views 0

SimpliTrain Finds its Groove in the LMS Arena Out here in Delray Beach, SimpliTrain's making waves in the Learning Management System (LMS) market, recently snagging the 'Pervasive Player' tag from MarketsandMarkets' 360Quadrants platform. This cloud-based learning powerhouse ain't just playing around; they're doubling down with expansion into AI and other fancy tech bits...

Continue Reading

Top 5 Most Recently Viewed Articles

Allied Gold and Ambrosia Forge Strategic Alliance for Growth

Updated Category News Views 126

Allied Gold and Ambrosia Forge Strategic Alliance for Growth Allied Gold Corporation (TSX: AAUC) is excited to share its new strategic partnership with Ambrosia Investment Holding. This partnership signifies a forward stride in leveraging the capabilities of both entities, aimed particularly at enhancing operations at the Sadiola mine. Understanding the Partnership The...

Continue Reading
DeepRoute.ai Showcases Innovative VLA Model at Major Event

Updated Category News Views 194

DeepRoute.ai Showcases Revolutionary VLA Model at Global Event DeepRoute.ai is making headlines as it unveils its innovative Vision-Language-Action (VLA) model at a prestigious mobility event in South Korea. This release marks a pivotal point in the company's goal to aid global automakers in harnessing AI technology for advanced mobility solutions. The VLA model is...

Continue Reading
Zions Bancorporation Announces Declared Dividends for Investors

Updated Category News Views 262

Zions Bancorporation Declares Quarterly Dividends Zions Bancorporation, N.A. (NASDAQ: ZION) has made an important announcement regarding its ongoing commitment to rewarding shareholders. The board of directors has declared a regular quarterly dividend of $0.43 per common share. This dividend will be payable to shareholders of record at the close of business on a specified...

Continue Reading
Sperm Bank Market Projected to Reach $8.57 Billion by 2033

Updated Category News Views 54

Growth of the Sperm Bank Market The global sperm bank market is on a significant upward trajectory. Recently valued at USD 5.54 billion, it is projected to reach USD 8.57 billion by 2033, growing at a compound annual growth rate (CAGR) of 4.45% from 2024 to 2033. This impressive growth can be attributed to several factors, including advancements in reproductive...

Continue Reading
Neuronetics Highlights Advances in Mental Health Technologies

Updated Category News Views 205

Neuronetics Showcases Commitment to Mental Health Innovation MALVERN, Pa. — Neuronetics, Inc. (NASDAQ: STIM), a pioneering company in medical technology focused on mental health care, is taking bold steps to enhance patient outcomes through innovation. With a steadfast commitment to making mental health care accessible, Neuronetics is excited to announce significant...

Continue Reading